Skip to main content
. 2014 Nov 14;65(1):124–133. doi: 10.1136/gutjnl-2014-307545

Figure 5.

Figure 5

STK33KOflox/flox, Alb-ERT2-Cre mice are resistant to diethylnitrosamine (DEN)-induced liver tumorigenesis. (A) Incidence of visible tumours in tamoxifen (TAM)-pretreated Alb-ERT2-Cre, STK33KOflox/flox and STK33KOflox/flox, Alb-ERT2-Cre mice treated with 50 μg/g DEN at the age of 20 days and killed 10 months later. (B) The number of tumours counted on the surface of liver lobes. (C) Tumour size measured on the surface of liver lobes. (D) Incidence of preneoplastic foci, hepatocellular adenoma and hepatocellular carcinoma in DEN-treated Alb-ERT2-Cre, STK33KOflox/flox and STK33KOflox/flox, Alb-ERT2-Cre mice. Data are expressed as percentage of total number of mice. (E) Representative images of Ki67 staining from DEN-induced tumours in Alb-ERT2-Cre, STK33KOflox/flox and STK33KOflox/flox, Alb-ERT2-Cre mice. For (A)–(E), mice were treated with 50 μg/g DEN at age 20 days and killed 10 months later. n=10 for Alb-ERT2-Cre group, n = 12 for STK33KOflox/flox and STK33KOflox/flox, Alb-ERT2-Cre groups. *p<0.05, **p<0.01, ***p<0.001.